FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours nor resnance:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PRESTRELSKI STEVEN						2. Issuer Name and Ticker or Trading Symbol XERIS PHARMACEUTICALS INC [XERS]								eck all applic Directo	able)	ng Person(s) to Issuer 10% Owner Other (specify below)		ner	
(Last) (First) (Middle) C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1810						3. Date of Earliest Transaction (Month/Day/Year) 06/25/2018								Chief Scientific Officer					
(Street) CHICAC	GO II	state)	60601 (Zip)	a Davi	-	4. If Amendment, Date of Original Filed (Month/Day/Year) vative Securities Acquired, Disposed of, or Benefic								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		on Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A)		d (A) or	5. Amour Securitie Beneficia Owned F	s illy ollowing	Form	: Direct I Indirect E str. 4) (7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)		((Instr. 4)		
Common Stock 06			06/2	25/20	5/2018					30,232	(2) A	(1)	482	482,193		D			
Common Stock 06			06/2	25/20	5/2018					7,130 [©]	3) A	(1)	489	489,323		D			
			Table II -								osed of, onvertib			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day)	oate,		ransaction code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis Expiration Date (Month/Day/Ye		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti	e O s Fe lly D oi (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Series A Preferred Stock	(1)	06/25/2018			С			53,849 ⁽²⁾	(1)		(1)	Common Stock	30,232	(1)	0		D ⁽²⁾		
Series B Preferred	(1)	06/25/2018			С			12,701 ⁽³⁾	(1)		(1)	Common Stock	7,130	(1)	0		D ⁽³⁾		

Explanation of Responses:

- 1. Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date.
- 2. 24,509 of these shares are held by Steven Prestrelski, and 29,340 of these shares are held by Steven Prestrelski and Tracy Yeo.
- 3. These shares are held by Steven Prestrelski and Tracy Yeo.

Remarks:

/s/ Barry Deutsch, as Attorney-

06/26/2018

in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.